Clinical DevelopmentTuspetinib is shaping up to be a welcome addition to first-line advanced AML.
Safety And EfficacyCombination therapy is safe and well tolerated.
Treatment PotentialIncorporating TUS into r/r AML treatment regimens could permit treatment of more patients, improvement in safety outcomes, enhancement of survival outcomes, and avoiding common first-line therapeutic failures.